The Dendritic Cell Dilemma in the Skin: Between Tolerance and Immunity

Nils Scheib1, Jessica Tiemann1, Christian Becker1, Hans Christian Probst2, Verena Katharina Raker1* and Kerstin Steinbrink1

1 Department of Dermatology, University Hospital, Westfälische Wilhelms-University Münster, Münster, Germany, 2 Institute for Immunology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany

Dendritic cells (DC) are uniquely capable of initiating and directing immune responses. The range of their activities grounds in the heterogeneity of DC subsets and their functional plasticity. Numerical and functional DC changes influence the development and progression of disease, and correction of such dysregulations has the potential to treat disease causally. In this review, we discuss the major advances in our understanding of the regulation of DC lineage formation, differentiation, and function in the skin. We describe the alteration of DC in disease as well as possibilities for therapeutic reprogramming with a focus on tolerogenic DC. Because regulatory T cells (Treg) are indispensable partners of DC in the induction and control of tolerance, we pay special attention to the interactions with these cells. Above all, we would like to arouse fascination for this cell type and its therapeutic potential in skin diseases.

Keywords: treg cells, tolerance, dendritic cells, cellular immunotherapy, DC targeted vaccines, interleukin 10

INTRODUCTION: DC SUBTYPES AND ONTOGENY

In humans, the haematopoiesis is initiated in the yolk-sac around days 16-18 of estimated gestational age (EGA), followed by the migration of immature hematopoietic stem cells, derived from the aorta-gonad-mesonephros, to the definitive location of pre-natal haematopoiesis; the fetal liver (1, 2). The adult myeloid compartment originates from precursor cells within the bone marrow. Common myeloid progenitors (CMP) have the ability to differentiate towards all adult myeloid cells in humans. The myeloid progenitor cell loses its capacity to produce megakaryocytes, erythroid, eosinophil and basophil cells as they become granulocyte macrophage DC progenitors (GMDP). GMDPs eventually acquire the phenotype of macrophage DC progenitors (MDP), which give rise to monocytes or CD123+ common DC progenitors (CDP). The latter is capable of differentiating towards CD141+ DC type 1 (cDC1) or CD1c+ DC type 2 (cDC2), as well as CD123+ plasmacytoid dendritic cells (pDC). Villani et al. (3) identified two distinct populations within cDC2 in blood and showed that CLEC9a could serve as a more suitable marker to identify cDC1 compared to CD141. Besides the bone-marrow precursors, monocytes can replenish the DC reservoir especially during inflammation (4). It appears that monocyte-derived DC (moDC) arise
primarily from CD14+CD16+ monocytes and carry the markers CD1c and CD1a in addition to CD11c (Table 1).

In humans, cDC1 and cDC2 are located in the dermis. Furthermore, the inflammatory environment in the skin promotes the development of moDC and the recruitment of pDC. The epidermis harbours Langerhans cells (LC) which are marked by the expression of Langerin, CD1a and E-cadherin (5). Although they demonstrate functional characteristics of DC, LC have been reclassified as tissue-resident macrophages (6). The same is true for dermal CD14+ cells, previously defined as DC, which most likely represent monocyte-derived macrophages (2). Lineage-tracing experiments in mice deciphered the role of transcription factors in DC development: cDC1 differentiation involves the transcription factors IRF8, IRF4, Id2 (7) and Batf3. Batf3 and IRF8 in particular appear to be indispensable for cDC1 development (5). Differentiation towards cDC2 in mice requires the expression of Id2 and Zeb2 (8), but IRF4 and Notch2/KLF4 expression is also required (5). Differentiation towards pDC requires the expression of IRF8 and IRF4 (5). Furthermore, ZEB2, a protein involved in epithelial-mesenchymal transition, has been described as a critical factor for the development of pDC. Deletion of zeb2 in murine bone marrow precursors lead to a drastic reduction of pDC in vitro and in vivo, presumably through the abrogation of zeb2-induced repression of id2. Loss of ZEB2 favours the development of cDC1 above pDC and appears to be of critical importance for the fate choice of CDP. Finally, moDC formation depends on the transcription factors MAFB and KLF4 (5) (Table 1).

Yolk-sac derived macrophages serve as transient progenitors of LC, but monocytes derived from the fetal liver replace them later on (9). In the adult skin, LC are self-sustaining with no contribution of bone marrow-derived cells (10). In mice, CSFR-1 receptor engagement (11) as well as transcription of runx3 and id2 are substantial in the maintenance of LC homeostasis.

In addition to phenotypic-functional classifications, DC classify by their migratory capabilities and differentiation stage. Attempts have been made to distinguish resident DC from migrating DC based on markers. For example, resident DC (pDC or cDC subgroups such as CD8+ DC or CD8/CD11b+ DC) in lymphoid organs (12) or migrating DC from peripheral tissues and non-lymphoid organs (including CD103+/Langerin+/CD11b+) can be distinguished (13). However, however, all DC migrate both in steady state and in inflammation. In the blood, a population of pre-DC forms a subset that is functionally distinct from pDCs and cDCs. AXL and Siglec6 (CD327) expressing cells (AS DC) strongly stimulate T cells in lymphoid tissue. As DC may also represent a mature cDC2 progenitor and are likely in transition to this subgroup (3).

The description of immature (iDC) and mature (mDC) phenotypes primarily refers to the maturation of DC in vitro.

**Table 1** | Overview of the most important markers of the DC populations.

| Transcription factor | moDC Pre-pDC/AS DC | pDC cDC1 cDC2 LC |
|----------------------|---------------------|-------------------|
| MAFB                 | Zbe2               | IRF8              | BATF3 | IRF4 I 
| KLF4                 | I 
| IF 
| IRF4                 | IF 
| IF 
| KLF4                 | Zeb2              | IRF8  
| IF 
| IF 
| PU1                  | Flt3L              | E2-2              |
| Zbtb46               | ID2                | RUNK3             |
| Main phenotypic cell marker | CD1c+ CD1a+ D11b+ CD103- CD11c CX30R1 CD172a (Sirpα) CD64(FcεR1) CD206+ | CD123+ CD303+ CD11c CD11c CD303+ CD11a+ AXL SIGLEC6 CX30R1 CD172a (Sirpα) |
| Extended phenotypic cell marker | CD123+ CD303+ CD303+ CD11c AXL SIGLEC6 CX30R1 | CD141+ CD103+ CD11b+ CD11c CD4 Langerin CD4+ Btla |
| Origin | BM-HSC BM-HSC BM-HSC BM-HSC BM-HSC | Embryonic progenitor, 
| Differentiate | Lymphoid and non lymphoid tissue Lymphoid and non lymphoid tissue BM Lymphoid and non lymphoid tissue Lymphoid and non lymphoid tissue |
| Migration/Occurrence | LN, spleen, thymus, blood LN, spleen, thymus, blood LN, spleen, thymus, blood LN, spleen, thymus, blood Through dermis into LN |
So-called iDC express CD11c but little major histocompatibility complex class II (MHC-II) and costimulatory molecules such as CD80, CD83 and CD86, while mDC show an upregulated expression of these costimulatory molecules as well as MHC-II (14). Maturation also occurs in vivo, of course, and the markers described in vitro are similarly altered.

KEY QUESTIONS AND FUTURE DIRECTIONS FOR THE FIELD

The increasing use of scRNA-seq has led to the description of additional DC subtypes. Transcriptomes, however, incompletely reflect the cell state as gene transcription is stochastic, characterized by transcriptional bursts of varying intensity (15) and half-lives of individual mRNA molecules vary considerably (16). Therefore, there is a need to determine whether the putative heterogeneity of DC, as evidenced by scRNA-seq, also reflects functional differences.

DENDRITIC CELL FUNCTIONS

DC are versatile cells that act as sensors for pathogens and gatekeepers of tolerance at the same time. They link innate signals (pattern recognition and early inflammatory mediators) to adaptive immune responses (T cell priming and Treg induction). DC functions are diverse and highly dependent on circumstances such as cytokines, tissue and cell origin. DC properties, including surface molecules and secreted soluble mediators, can result in tolerogenic as well as stimulatory effects. This means that their function can be beneficial in relation to peripheral tolerance induction or disadvantageous as in transplant rejection (17).

DC decide on the quality and quantity of the immune response simply by their degree of activation (Figure 2). As professional antigen-presenting dendritic cells (APCs), they take antigens from their environment, process them and provide costimulation that can prime naive T cells unlike any other MHCII-carrying cell in the body.

Factors that drive DC activation are hallmarks of infection and inflammation such as danger (DAMP) or pathogen-associated molecular patterns (PAMP) as well as inflammatory cytokines. DAMPs are molecules or cellular structures released because of cell death or trauma, as heat shock proteins, histones and mitochondrial components. PAMPs are components of pathogens such as LPS, peptidoglycans or bacterial and viral nucleic acids. Recognition of PAMPs or DAMPs via toll-like receptors (TLR), C-type lectins or RIG-I-like receptors or sensing of inflammatory cytokines such as tumor necrosis factor (TNF) alpha, interleukins 1 and 6 via cytokine receptors (18) induces a differentiation program in DC that has been termed “mature” (18). Such mature DC then express costimulatory molecules, MHC-II and chemokine receptors, which facilitate migration to the lymphoid organs and secretion of elevated levels of inflammatory cytokines. It must be noted, however, that although a DC exhibits characteristics that are termed “mature”, it may have non-immunogenic functions such as tolerance maintenance. At specific anatomical sites (thymus) DC exert tolerogenic functions despite being in a potentially inflammatory environment. Interestingly in this regard is the NF-κB pathway. NF-κB is known as a target gene of TNF-α signalling but can also induce TNF-expression during DC maturation. Earlier reports suggest that NF-κB1 is involved in the repression of TNF-α expression in immature DCs by itself (19, 20). Steady-state DC actively induce a tolerance-promoting state (regulatory T-cell (Treg) induction) or render T-cells unresponsive (anergy) (21). Tolerogenic maturation has been shown to depend on IRF4, and ablation of IRF4 in DC impairs peripheral tolerance induction (22, 23) (Figure 1).

Interestingly, human tolerogenic DC (IL10-DC) matured in vitro in the presence of interleukin-10 induce functional regulatory T-cells regardless of their degree of maturation (CD83 low and high) (24, 25). In addition, DC express distinct toll-like receptors (TLRs), which supports their functional specialization, a process that is highly context- and thus cytokine-dependent. A tolerance-promoting function via IL-10 has been reported for (26, 27). Because of its barrier function, the skin also harbours commensal bacteria, which colonize the barrier and thus protect the body from colonization by pathogens. The immune system senses patterns expressed by skin commensals. As previously shown, CD103+ DC take up antigens or commensals in the skin or hair follicles and travel to the draining lymph nodes to activate T cells. Primed T cells then migrate back to the skin where they augment the antimicrobial properties of keratinocytes via T cell-produced IL-17 (28). Aside from being potent inducers of CD4+ and CD8+ T cell-mediated adaptive responses, DC can also have direct effects on bacteria. The production of TNF-α and inducible nitric oxide synthase (iNOS) by so-called TipDC has shown that DC can eliminate bacteria in the murine L. monocytogenes infection model. TipDC had allostimulatory capacity in mixed leukocyte reactions but were not required for effective priming of CD4 and CD8 T cells in vivo (29). Skin resident LC phagocytes act as skin guardians, orchestrate immune responses against pathogens, but have also been implicated to induce tolerance to skin’s own antigens under steady-state conditions (30, 31). Local ablation of epidermal LC worsened the dermal phenotype in a lupus mouse model but had no systemic effect on the effects of autoimmune responses. LC regulate skin tolerance via IL-10-producing CD4+ T cells, but IL-10 levels in skin-draining lymph nodes were unaffected (32) (Figure 1).

Human pDC constitutively express the serine protease granzyme B (GrB) (33). GrB production in human pDC is stimulated by IL-21 but inhibited by autocrine production of type I interferons (34). Similarly, IL-10 can increase GrB secretion from pDC, whereas Toll-like receptor agonists and CD40 ligand strongly inhibit them (35). GrB+ pDC suppress T cell proliferation in a GrB-dependent, perforin-independent manner, a process reminiscent of Treg. GrB-secreting pDC may therefore play a regulatory role in tumor immune defense, antiviral immune responses, and autoimmune processes. In inflammatory processes, CD8+ T cells trigger perforin-mediated apoptosis in pDC, limiting their proinflammatory activity and possibly avoiding autoimmunity (36).
KEY QUESTIONS AND FUTURE DIRECTIONS FOR THE FIELD

Future research in this field must link the phenotypic characterization of the different DC subpopulations to the known functions of DC biology. Is there really a large number of different DC or are there simply states of activation in certain organs at certain times that are functionally indistinguishable?

ALTERED DC FUNCTION IN DISEASE

As key cells of tolerance and immunity, dendritic cells are directly involved in the development and progression of diseases. Here, we would like to give examples of disease-causing and course-determining DC alterations in cutaneous tumors, autoimmune diseases, and inflammation of the skin.
SKIN CANCER

The DC network of the skin may be one of the first contacts that growing skin tumors have with the immune system. In what way such first contacts influence tumor growth is unclear. However, avoidance of inflammatory responses and immune cell immigration induced by them might help tumors to remain “cold,” i.e., not detected or even ignored by the immune system. If inflammation and immune cell immigration occur, tumors induce numerical and functional changes in progenitor cells and mature DC that attenuate or undermine the immune response against them. Following examples categorize DC alterations in skin cancer:

Altered DC Recruitment or Survival
Lesions of squamous cell carcinoma (SCC) have significantly reduced numbers of LCs and CD11c+ dermal DC, resulting in fewer DC available for effective T-cell priming (37, 38).

Melanomas recruit pDC via CXCR4/CXCL12 (39). IFN-induced expression of CXCR3 ligands (CXCL9, CXCL10, and CXCL11) produced by pDC in turn promotes the attraction of additional pDC (40). Through increased attraction, melanomas appear to recruit primarily immature pDC (also called plasmacytoid monocytes) (39).

Redirection of Monocyte Precursors
IL-6 and macrophage colony-stimulating factor (M-CSF) produced by melanomas promote monocyte differentiation into macrophages rather than DC, limiting effective T-cell responses (41). Melanomas concomitantly produce GM3 and GD3 gangliosides that inhibit DC differentiation from monocyte-derived progenitors and induce apoptosis in monocyte-derived DC (42, 43). Similarly, melanoma-derived cyclooxygenase-1 (COX-1) and COX2 prostanoids block DC differentiation (44).

Exploitation of Immature DC
Tumor-infiltrating immature DC and pre-DC promote angiogenesis in tumors by secreting endothelial growth factors (e.g., VEGF) and producing other factors that increase the sensitivity of endothelial cells to growth factors (45, 46). Conversely, tumors induce endothelial transdifferentiation in DC progenitor cells, which form a scaffold for the subsequent lining of tumors with endothelial cells (47).

DC Subversion
Skin tumors undermine anti-tumor immunity not only by altering the differentiation of DC precursors, but also by interfering with the activity of fully differentiated DC:

DC treated with melanoma lysate produce less IL-12p70 albeit without showing changes in maturation markers (e.g., CD40, CD80, CD83) (48). However, melanoma-infiltrating DC also appear to become resistant to some maturation stimuli (49). In turn, DC from regressing melanoma metastases exhibit a stronger T-cell stimulatory potential than DC in progressively growing metastases (50).

More recently melanomas have been found to convert infiltrating cDC2 cells into myeloid cells characterized by decreased CD1c expression and expression of monocyte/TAM markers such as CD14, CD163, CD206, and MerTK (51). Thus, CD14+ DC appear to arise not only from monocytes but can also develop from cDC2 in the tumor microenvironment (52). In a three-dimensional melanoma model with multicellular tumor spheroids, lactic acid produced by melanomas suppressed the production of proinflammatory cytokines, including IL-12, by monocyte-derived DC (53).

Melanoma-recruited pDC lose the propensity to produce type I interferons (IFN I), which play an important role in cancer immunization (54, 55). Such altered pDC then support melanoma progression by promoting regulatory immunity through OX40L and ICOSL (56).

Treg contribute to immune tolerance to tumors (57, 58) as evidenced by the fact that their ablation in mouse models improves the anti-tumor immune response (59). However, while early Treg deletion triggers complete rejection of transplanted tumors (60), deletion at later time points only limits tumor growth, suggesting that Treg establish mechanisms in the tumor microenvironment that become Treg independent. Nevertheless, depletion of Treg at late growth phases of tumors also increases the number of functional cytotoxic T cells in tumor tissue and enhances responses to vaccination against tumor antigens (60). However, some observations point to a more complex role for Treg in tumor growth. By limiting inflammatory processes that drive malignant transformation (61), Treg may protect against the development of certain tumor types (62). While sarcomas appear to escape, immune control via editing rather than immune repression, lung adenocarcinomas escape because the anti-tumor response itself was suppressed (63). Tumor-infiltrating T cells also often do not appear suppressed, but rather chronically activated and functionally altered (64, 65). Taking into account that Treg primarily form stable contacts with DC in tissues, the effect of Treg in tumors appears to be based less on regulation of T cells and more on DC. How tumor-induced changes in DC affect their interaction with Treg seems for the most part unexplored. It is also conceivable that tumor cells alone do not alter DC in tumors, but interaction with Treg does.

AUTOIMMUNE SKIN DISEASES

The development of autoimmune diseases bases on alterations in central or peripheral immune tolerance. As early as the 1980s [ten years after their discovery as a separate antigen presenting cell population (66)], DC were observed to act as drivers of T cells in autoimmune lesions (67) and to transfer autoimmunity to naive recipients (68).

Interestingly, observations made in the 1970s (69) that led to the definition of Foxp3+ Treg in the 1990s (70) are also closely related to autoimmune diseases. Foxp3+ Treg prevent autoimmunity by limiting activation and differentiation of
autoreactive T cells through interaction with DC (71), in particular, by regulating the expression of costimulatory molecules (72) and suppressing canonical autophagy (73).

Despite methodological difficulty in reliably identifying human Treg (74, 75), a number of papers have demonstrated that most autoimmune diseases are accompanied by defects in the number or function of peripheral blood Treg, and these observations could be confirmed by in vivo disease models (76). Most notably, experimental models demonstrated that attenuation of Treg activity is causally not just a consequence of autoimmune disease (77).

**Preventive Role in Autoimmune Pathogenesis?**

Novel models of constitutive and inducible DC ablation and DC-specific gene targeting have further elucidated the role of DC in autoimmune diseases. Enforced antigen expression in steady state DC induces profound and irreversible peripheral unresponsiveness. Both, induction of Treg and anergization or deletion of autoreactive T cells have been shown to be involved in peripheral tolerance induction by DC (21, 78–81). However, constitutive cDC, pDC or CD8+ cDC ablation (82–85) results in only a small reduction in Treg numbers but does not cause autoimmunity and DC ablation in an autoimmune-prone background ameliorates rather than exacerbates disease (86). However, these observations do not mean that DC are redundant for peripheral tolerance, because in the absence of DC, effector cells do not form.

Presumably, their functional state rather than their phenotype determines the tolerogenic properties of DC. Although distinct tolerogenic DC can be generated under artificial conditions (87, 88), they are not identifiable in the steady state. It has been suggested that expression of the autoimmune regulator (AIRE), which induces the presentation of a wide range of self-antigens, contributes to central and peripheral tolerogenic DC activity (89, 90), however, in human DC its association with tolerogenic DC activity has been called into question (91).

Independent of a phenotypic distinction of tolerogenic DC populations, there are observations showing that DC counteract autoimmunity by activating regulatory cells. In pemphigus, for example, LC counteract the development of autoimmunity by activating keratinocyte antigen-specific Treg (92).

**Contributing Role in Autoimmune Pathogenesis**

While early adoptive transfer experiments had already shown that DC can trigger autoimmunity responses (67, 68), a number of anti-inflammatory genes (including SHP1, STAT3, αβ integrin) have since been identified whose absence in DC triggers spontaneous autoimmune responses (93–95). In addition the formation of type I interferons by pDC appears to be involved in all autoimmune processes. Recent observations show that the gut microbiome induces IFN-I production in pDC, which drives a specific epigenomic and metabolic state in cDC that instructs cDC for pathogen control. Interestingly, however, IFN-I-mediated cDC instruction lowers the threshold for self-reactivity (96). In this context, it is noteworthy that of the 81 human autoimmune diseases identified by Hayter and Cook (97), most involve the barrier tissues gut and skin. As in the gut, a continuous confrontation with microbiota takes place in the skin (98). Whether this leads, as in the gut, to an instruction of skin DC is, to our knowledge, not investigated. On the other hand, there are increasing indications that gut commensal-mediated immune instruction becomes systemic and influences immune responses in the skin including autoimmune responses (99).

**Disease Repercussions on DC and Their Significance for Disease Progression**

In addition to changes in DC that drive the development of autoimmunity, there are retroactive changes in disease that determine disease progression.

**DC Accumulation and Altered Cytokine Formation**

Accumulation of pDC is characteristic of autoimmune skin lesions. In several autoimmune diseases, increased recruitment of DC to target tissues leads to a decrease in the number of DC in the blood. In rheumatoid arthritis (RA) there is also-possibly in response to the decrease in numbers in the blood- an increased generation of pre-plasmacytoid dendritic cells in bone marrow (100). In systemic lupus erythematosus (SLE) circulating pDCs become functionally abnormal (101).

**Defective Migration**

Local immune activation, in addition to increased attraction of pDC, also ensures that DC already in the tissue increasingly migrate to draining lymph nodes, or, conversely, are retained at the site of inflammation. For example, in autoimmune dermatitis, the migration of LC is impaired (102). The defect in LC migration develops before the onset of skin lesions and correlates with the onset and severity of dermatitis. However, there appear to be both non-migrating LC and migrating cells that look like LC and share some of their characteristics (103).

**INFLAMMATORY SKIN DISEASES**

Inflammatory skin diseases are due to barrier damage or activation of innate and acquired immunity. In contrast to defined autoimmune diseases, inflammatory skin diseases often have an autoimmune component for which it is not conclusively clear whether it is causal.

**Psoriasis**

Psoriasis is a common (2% of the U.S. population) chronic inflammatory skin disease characterized by thickening and scaling of the epidermis due to increased proliferation of keratinocytes (104). Psoriasis often develops on damaged skin (Köbner phenomenon), suggesting that innate danger signals may trigger psoriatic inflammation. It is now widely believed that psoriasis is of autoimmune origin (105, 106).
Psoriasis is associated with a greatly increased number of inflammatory DC in diseased skin that act as potent T-cell activators (107). In both psoriasis and relevant mouse models, the IL-23/IL-17/IL-22 axis plays an important role in the disease. In IL-23-induced psoriasis and in Imiquimod-induced psoriasis (a model based on the observation that patients treated with Aldara cream experience flares of psoriasis (108), which most closely match gene expression found in psoriatic skin (109)), the critical DC are TNF-α and IL-1β-producing monocyte-derived DC, including a population of Inflammatary Langerhans cells. FIt3L-dependent DC and resident LC appear to be dispensable for inflammation (110).

Lichen Planus
Lichen planus is a chronic recurrent inflammatory disease of the skin and mucous membranes associated with apoptosis of basal keratinocytes (111). For some time, autoimmune T cells against desmoglein 3- and COL17 have been suspected to play a role in this disease (112). Studies on DC indicate that LC play roles in the pathology of the disease as they accumulate alongside DC in oral lymphoid foci (113). As in virtually all skin autoimmune diseases, in addition to myeloid DC, pDC were observed to secrete IFN-α and granzyme B and possibly help lymphocytes in tissue destruction.

Herpesvirus infections are associated with several autoimmune diseases, including SLE, multiple sclerosis (MS), and RA (114). Importantly, HSV infect DC and alter their function (115). Remissions of lichen planus have been associated with a decrease in protein expression of HHV-7 herpesviruses in pDC (116). Either viruses infect inflamed skin more easily or viral infections lead to the destruction of keratinocytes and thus start reactions against self-antigens.

KEY QUESTIONS AND FUTURE DIRECTIONS FOR THE FIELD
The study of human disease in relation to the role of DC struggles with the chicken-and-egg problem. Are DC drivers of the disease or are changes in DC merely a consequence of the disease? Mouse models of skin diseases such as psoriasis recapitulate the symptoms of psoriatic patients, but are based on triggers that do not occur as such in the pathogenesis of human diseases. In addition, it is unclear which molecules define tolerogenic and immunogenic DC.

THERAPEUTIC DC REPROGRAMMING

In Vivo Targeting of DC for Therapeutic Approaches
The important potential use of tolerogenic DC in immunotherapeutic applications include allergic and autoimmune disorders and transplantation medicine. Thus, methods for rapid and reliable large-scale production of DC ex vivo from peripheral blood of patients have been of great academic and clinical interest and multiple clinical studies have been performed as mentioned below. However, difficulties in obtaining DC from the blood in sufficient numbers, high manufacturing costs and comprehensive requirements for GCP-based production have led to advancements for in vivo targeting of per se tolerogenic DC or for induction of tolerogenic phenotypes in vivo, respectively (117–119). In addition to avoidance of costly ex vivo isolation, these approaches have the advantage of targeting of DC subsets in their natural environment and offer the availability to a broad range of patients because of donor independency (Figure 2).

ANTIBODY-MEDIATED DC TARGETING IN VIVO
An alternative strategy for antigen-specific tolerance induction by DC in vivo is the use of antigen-delivering antibodies (119, 120). Here, a particular antigen is delivered via antibodies that bind to molecules expressed by DC. The rationale is the specific targeting of tolerogenic DC and/or the induction of intracellular tolerogenic pathways after internalization and processing of the antigen (Figure 2). So, the processed antigen will be presented in a tolerogenic context, resulting in T cell anergy, T cell deletion, and/or activation and expansion of Treg, respectively. Though many studies focus on the induction of immunity in cancer, in vivo targeting of DC was achieved to affect the immune responses in allergies, autoimmune diseases and transplantation rejections as well. Antibody-dependent targeting of DEC-205, an endocytotic receptor highly expressed on cDC1, resulted in antigen-specific unresponsiveness in the absence of adjuvants, whereas presence of maturation stimuli led to pronounced immune responses (21, 118). With regard to the pro-tolerogenic properties of DEC205 DC if given without adjuvants, antibodies against the c-type lectin receptor DEC205 have been administered in different mouse models of autoimmune diseases (e.g. EAE, diabetes, colitis and arthritis) and graft-versus-host disease (121–125), resulting in tolerogenic mechanisms and prevention of inflammatory immune reactions. Dependent on the type of disorder and the antigen used, T cell deletion or T cell anergy of antigen-specific effector T cells and/or Treg activation have been identified as underlying mechanism for tolerance induction. Importantly, a phase I clinical trial in which human DC were targeted in vivo with anti-DEC205 linked to the tumor antigen NY-ESO-1 in the presence of maturation factors resulted in a robust cellular and humoral immune response. This proof-of-concept study confirms the preclinical data that in vivo targeting of DC leads to an antigen-specific modulation of immune reactions (126). Further studies reported alternative molecules for antibody-mediated targeting of tolerogenic DC as CD207, Tremh4, Siglecs, DCIR2, or CLEC9A (DNGR1). Antigen delivery by these antibodies in the vast majority of the studies promoted the activation and/or differentiation of regulatory FOXP3+ regulatory T cells (118, 127) (Figure 2).
USE OF NANOPARTICLES FOR TOLEROGENIC DC TARGETING IN VIVO

Driven by the initial success in DC-targeting nanocarriers for cancer treatment, promising strategies in this field are under development to modulate the immune system in autoimmunity, allergies, and transplantation medicine (128). DC-specific antibodies can be linked to nanoparticles (NP), allowing for a cell-specific targeting, as well as drug-delivery to induce DC with a tolerogenic phenotype, thereby preventing harmful inflammatory immune responses (Figure 2). For successful nanoparticle-based immune modulation through DC targeting in vivo, there are some aspects to be considered: 1. physicochemical properties of the NP (material, size, shape, charge, surface modification etc.), 2. disease-specific antigens, 3. DC targeting molecules, 4. co-delivery of drugs or adjuvants with functional properties for tolerance induction and 5. route of administration (119, 128). When using nanoparticles for regulation of immune reactions in autoimmune and allergic diseases, all these parameters can be optimized to boost DC targeting and to control unwanted immune responses. Multiple receptors, including DC-SIGN, mannose and Fc receptors, CD40, or CD11c, respectively, have been used for DC specific targeting in the context of nanomedicine (128).

Immunosuppressive drugs and other tolerogenic agents (e.g. siRNA, antisense oligonucleotides) can be packaged into nanoparticles and be co-delivered with (auto-)antigens into DC, resulting in immune tolerance, e.g. by generation and activation of Treg (129) (Figure 2). In preclinical in vivo models it was demonstrated that poly(lactic-co-glycolic acid) (PLGA) nanoparticles carrying rapamycin were capable of inducing durable immunological tolerance to co-administered proteins via induction of tolerogenic DC and subsequent increased numbers of Treg. This immune modulation resulted in an inhibition of antigen-specific hypersensitivity reaction that was superior to the efficacy of rapamycin administered on its own (130). In another approach, nanoparticles were generated that target disease relevant peptides toward MHC class II molecules which then initiate the expansion of antigen-specific regulatory Tr1 cells and regulatory B cells leading to abrogated immunological and clinical symptoms in several murine autoimmune models such as type 1 diabetes, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease (131). The field of transplantation medicine uses nanoparticles to induce a donor-specific, long-lasting tolerance. Bryant et al. showed that PLGA-based nanoparticles loaded with donor antigens combined with low dose rapamycin at the time of transplant protected transplanted islet allografts from rejection (132).

THE SKIN AS ANATOMICAL SITE FOR DC – MEDIATED TOLERANCE INDUCTION

Among specific anatomical sites, the skin represents a crucial barrier that is in constant exchange with exogenous antigens and commensal pathogens, requiring control of immune responses orchestrated by cutaneous and skin-draining DC. As mentioned above, the induction of tolerance vs. immunity depends on the DC subset, immune mediators and receptors involved etc. but as well as on the dose and application route of the antigen. With regard to the antigen dosage, the allergic contact dermatitis (ACD), one of the most frequent occupational skin disorder, is induced in patients and mice by epicutaneous exposure to high doses of contact allergens (haptens). They are taken up by cutaneous DC that prime the allergen-specific ACD effector T cells in the skin-draining LN. A second contact with the same allergen results in activation of these allergen-specific ACD effector T cells and the clinical manifestations of the ACD (133, 134). In contrast, repetitive epicutaneous applications of very low doses of haptens (low zone tolerance) circumvent the activation of cutaneous DC and in contrast induce an allergen-specific tolerance via stimulation of regulatory FOXP3+ T cells and activation and differentiation of CD8⁺ tolerogenic DC in skin-draining LN. The latter ones produce TNF that foster the apoptosis of ACD effector T cells, thereby inhibiting the allergic cutaneous inflammation of ACD (135-137) (Figure 2). Thus, the dosage of the contact allergen determines the outcome of the immune response and the development of the resulting skin disease via activation of stimulating vs tolerogenic DC, followed by regulatory T cell differentiation respectively.

The idea to modulate an allergic immune response by application of allergens via the skin was also further analysed for protein antigens, and called epicutaneous immunotherapy (EPIT) (138). In animal models of food allergies and autoimmune diseases, repetitive applications of an adhesive dermal patch containing antigens protect from inflammation and clinical symptoms via uptake of antigens by cutaneous LC and subsequent regulatory T cell activation (119, 138, 139) (Figure 2). These promising studies have paved the way for several clinical trials of EPIT that have been completed or are ongoing for milk, peanuts and pollen allergies with encouraging results in terms of safety and tolerability (138).

CLINICAL TRANSLATION OF TOLEROGENIC DC

For clinical applications, the most available options so far have been to induce immature DC ex vivo, and treat them with agents promoting the differentiation into tolerogenic DC phenotypes, which can be given during the entire culture period in the absence of maturation stimuli or only during the maturation phase. The latter protocols combine the culture of CD14⁺ DC precursor cells in the presence of maturation factors (e.g., LPS or IL-1“IL-6”TNF”PGE2) with additional pharmacological agents, immunosuppressive mediators, exposure to apoptotic cells or gene modification (119, 140, 141). Here, an aberrant DC maturation occurs, resulting in the differentiation of a stable human tolerogenic DC phenotype. Such monocyte-derived DC recapitulate the properties and functionality of naturally occurring DC. Co-culture of monocyte-derived DC with immunosuppressive drugs (e.g. rapamycin, dexamethasone) or...
cytokines (e.g. TGF-beta, IL-10) or other bioactive agents (e.g. vitamin D3, hepatocyte growth factor, complement factor H, neuropeptide vasoactive intestinal peptide) leads to tolerogenic properties of the differentiated DC populations (140, 142–148). Most of these substances dampen the antigen-presenting properties of DC by reducing expression of costimulatory and MHC class molecules. On the other hand, immunosuppressive surface molecules (e.g. ILTs, PD-L1) or soluble mediators (IL-10, TGF-beta, IDO) are highly expressed by tolerogenic DC subsets (145, 149–151). These differentiated tolerogenic DC are capable to directly suppress the effector functions of other immune cells, such as T or B cells, induce T cell anergy or T cell apoptosis and/or the differentiation and activation of Treg with high suppressive activity.

Since a comparative study by Boks et al. identified IL-10 modulated tolerogenic DC as promising candidates for antigen-specific tolerance induction in vitro, we will highlight the generation and properties of these DC subset in more detail. In the first culturing step IL-10 DC differentiate in the presence of IL-4 and GM-CSF to immature DC. The two most prominent protocols differ in the duration of IL-10 supplementation: throughout the culture period (DCIL10) or only during the last two days of culture, in the presence of a maturation cocktail (25, 152–156). Gregori et al. showed that DCIL10 express CD14, CD16 and ILT2-4 but also typical DC markers such as CD83 and CD86 molecules (156). DCIL10 are inducers of regulatory IL10 secreting Tr1 cells that express CD49b and Lag3 and the induction of these Tr1 cells was largely dependent on IL-10 secretion by DCIL10.

In contrast, human IL-10 DC, generated in presence of IL-10 only during the last two days of the maturation phase, were inducers of anergic T cells as well as of Treg, which was independent of IL-10 secretion by DC. The Treg efficiently suppressed syngeneic CD4+ effector T cells and cytotoxic CD8+ T cells in a cell-to-cell contact dependent and antigen-specific manner (142, 153). The induced T cell anergy was associated with an increased expression of MAP kinase p38 and its effector molecules MEK 2 and 3. The latter ones facilitated the upregulation of the cyclin-dependent inhibitor 1B (p27Kip1), resulting in a cell-cycle arrest in the G1 phase and, thereby in an anergic state of the T cells (154, 155).

As mentioned above, a comparative study by Boks et al. identified IL10-modulated DC (IC-10 DC) as the most potent candidates for tolerance induction as they exhibit important prerequisites for clinical applications in humans such as potent migratory capacity, efficient Treg induction, and the stability of tolerogenic phenotype under inflammatory conditions (146). Investigation of our own laboratory confirmed these theses as we identified two subsets of the tolerogenic IL-10 DC, CD83highCCR7+ and CD83lowCCR7+ IL-10 DC. Both tolerogenic DC subpopulations exhibited the capacity to induce Treg, but Treg generated in the presence of the CD83high IL-10 DC subset displayed a superior suppressive capacity. In addition, the CD83high DC subset was extremely stable in a pro-inflammatory environment and, due to the increased CCR7 expression showed a very high migratory capacity which is required for DC/T cell-contact in lymphatic tissues (25), identifying this CD83highCCR7+ IL-10 DC subset as promising candidate for clinical applications.

Clinical Studies With Ex Vivo Generated Human Tolerogenic DC

The increasing knowledge of tolerogenic DC biology, the promising results from in vitro studies with human DC and numerous preclinical animal studies have paved the way for several completed and ongoing clinical phase I trials in autoimmune diseases and transplantation medicine (141) (Figure 3). Published studies in patients suffering from diabetes (157), arthritis (158, 159), multiple sclerosis (160, 161) and Crohn’s disease (162) used different protocols for induction of tolerogenic DC phenotypes, including dexamethasone alone or plus vitamin D3 or vitamin A, respectively. Vitamin D3 alone, an NF-kappaB inhibitor, or antisense ODN against CD40, CD80 and CD86 were also used. In the vast majority of the trials the tolerogenic DC were loaded with disease specific antigens/peptides for induction of a specific tolerance reaction. The study results demonstrated a range from no adverse effects until grade 1/2, indicating a high safety profile for tolerogenic DC applications in vivo. Analysis of the clinical outcome showed a therapeutic response in a part of the patients, often measured in reduction of disease-specific scores. Immuno-monitoring in some trials revealed a decrease in cytokine production, reduced effector T cell responses, and intriguingly, an increase of the Treg/effector T cell ratio or of the frequency of the Tr1 regulatory T cell subset (158). These results demonstrate that regulatory cell therapy is associated with fewer infectious complications, but similar rejection rates, and is therefore a potentially useful therapeutic approach to minimise the burden of general immunosuppression (163). A meta-analysis of 48 records of clinical trials confirmed these data, showing the safety of tolerance-inducing cell-products (including DC) in patients with autoimmune disorders or receiving organ transplantation (160).

KEY QUESTIONS AND FUTURE DIRECTIONS

In general, the clinical trials in this field have confirmed the safety and feasibility of autologous ex vivo generated tolerogenic DC for therapeutic approaches in autoimmunity and transplantation medicine. However, tolerogenic DC use in real clinical practice has many problems to solve beforehand. Harmonization of study protocols and systematic inclusion of immunological outcome measures would highly improve the development of tolerogenic DC-based treatment approaches.

The needs have initiated the implication of consortia in the USA (“The immune tolerance network”) and Europe (“Action to focus and accelerate cell-based tolerance inducing therapies”). As the generation of autologous ex vivo tolerogenic DC exhibit several pitfalls as mentioned, alternative strategies of in
vivo DC targeting by antibody- and nanoparticle-based techniques or antigen delivery by way of the skin (EPIT, LZT) can be considered for tolerance induction. However, these systems have been primarily tested in preclinical models and further translational trials have to be performed to show the efficacy, feasibility and safety of these novel strategies for tolerance induction via DC targeting in vivo.

AUTHOR CONTRIBUTIONS

CB, VR, and KS contributed to conception and design of the manuscript. NS, CB, VR, and KS wrote the first draft of the manuscript. HP wrote sections of the manuscript. VR designed figures and JT created table 1. All authors contributed to manuscript revision, read, and approved the submitted version.

FUNDING

This work was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) with TR156/A4/C05-246807620, SFB1009/B11-194468054, SFB1066/B06-213555243 and SFB1450/C06-431460824 (all to KS), TR156/C5-246807620 (to VR), TR156/B02-246807620 (to HP), SFB1066/B08-213555243 (to CB).

REFERENCES

1. Hettinger J, Richards DM, Hansson J, Barra MM, Joschko A-C, Krijgsveld J, et al. Origin of Monocytes and Macrophages in a Committed Progenitor. Nat Immunol (2013) 14:821–30. doi: 10.1038/ni.2638
2. McGovern N, Chan JKY, Ginhoux F. Dendritic Cells in Humans: From Fetus to Adult. Int Immunol (2015) 27:65–72. doi: 10.1093/intimm/dxu091
3. Villani AC, Satija R, Reynolds G, Sarkizova S, Shkhar K, Fletcher J, et al. Single-Cell RNA-Seq Reveals New Types of Human Blood Dendritic Cells, Monocytes, and Progenitors. Science (2017) 356:aah4573. doi: 10.1126/science.aah4573
4. Mehta H, Angsana J, Bissonnette R, Munoz-Elias EJ, Sarfati M. Inflammatory Skin Disorders: Monocyte-Derived Cells Take Center Stage. Front Immunol (2021) 12. doi: 10.3389/fimmu.2021.691806
5. Collin M, Bigley V. Human Dendritic Cell Subsets: An Update. Immunology (2018) 154:3–20. doi: 10.1111/imn.12888
6. Doebel T, Voisin B, Nagae K. Langerhans Cells - The Macrophage in Dendritic Cell Clothing. Trends Immunol (2017) 38:817–28. doi: 10.1016/j.it.2017.06.008
7. Wu XD, Briseno CG, Grajales-Reyes GE, Haldar M, Iwata A, Kretzer NM, et al. Transcription Factor Zeb2 Regulates Commitment to Plasmacytoid Dendritic Cell and Monocyte Fate. Proc Natl Acad Sci U S A (2016) 113:14775–80. doi: 10.1073/pnas.1611408114
8. Scott CL, Soen B, Martens L, Skrypek N, Saelens W, Taminou J, et al. The Transcription Factor Zeb2 Regulates Development of Conventional and Plasmacytoid DCs by Repressing Id2. J Exp Med (2016) 213:897–911. doi: 10.1084/jem.20151715
9. Hoeffel G, Wang YL, Greter M, See P, Teo P, Malleret B, et al. Adult Langerhans Cells Derive Predominantly From Embryonic Fetal Liver Monocytes With a Minor Contribution of Yolk Sac-Derived Macrophages. J Exp Med (2012) 209:1167–81. doi: 10.1084/jem.20120340
10. Mildner A, Jung S. Development and Function of Dendritic Cell Subsets. Immunity (2014) 40:642–56. doi: 10.1016/j.immuni.2014.04.016
11. Ginhoux F, Tacke F, Angeli V, Bogunovic M, Loubau M, Dai XM, et al. Langerhans Cells Arise From Monocytes In Vivo. Nat Immunol (2006) 7:265–73. doi: 10.1038/ni1807
12. Segura E. Review of Mouse and Human Dendritic Cell Subsets. Methods Mol Biol (2016) 1423:3–15. doi: 10.1007/978-1-4939-3606-9_1
13. Balan S, Saxena M, Bhardwaj N. Dendritic Cell Subsets and Locations. Int Rev Mol Cell Biol (2019) 348:1–68. doi: 10.1016/bbcmcb.2019.07.004
14. Patente TA, Pinho MP, Oliveira AA, Evangelista GCM, Bergami-Santos PC, Barbuto J. Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy. Front Immunol (2019) 9. doi: 10.3389/fimmu.2018.03176
15. Larsson AJM, Johnsson P, Hagemann-Jensen M, Hartmann L, Faridani OR, Balan S, Saxena M, Bhardwaj N. Dendritic Cell Subsets and Locations. Trends Immunol (2016) 37:149–50. doi: 10.1016/j.jimmunol.2017.03.016
16. Segura E. Review of Mouse and Human Dendritic Cell Subsets. J Immunol (2020) 176:1673–7. doi: 10.1088/jm.2015.67363
17. Patente TA, Pinho MP, Oliveira AA, Evangelista GCM, Bergami-Santos PC, Barbuto J. Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy. Front Immunol (2019) 9. doi: 10.3389/fimmu.2018.03176
18. Bermejo-Jambrina M, Eder J, Helgers LC, Hertoghs N, Nijmeijer BM, Segura E. Review of Mouse and Human Dendritic Cell Subsets. J Immunol (2020) 176:1673–7. doi: 10.1088/jm.2015.67363
19. Lutz MB, Schüler G. Immature, Semi-Mature and Fully Mature Dendritic Cells: Which Signals Induce Tolerance or Immunity? Trends Immunol (2016) 37:149–50. doi: 10.1016/j.jimmunol.2017.03.016
20. Dissanayake D, Hall H, Berg-Brown N, Elford AR, Hamilton SR, Murakami K, et al. Nuclear Factor-Kappab1 Controls the Functional Maturation of Dendritic Cells and Prevents the Activation of Autoreactive T Cells. Nat Med (2011) 17:1663–7. doi: 10.1038/nm.2556
21. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic Cells Induce Peripheral T Cell Unresponsiveness Under Steady State Conditions In Vivo. J Exp Med (2001) 194:769–79. doi: 10.1084/jem.194.6.767
22. Ardoniu L, Luche H, Chehbi R, Carpenter S, Shawket A, Montanana Sanchis F, et al. Broad and Largely Concordant Molecular Changes Characterize Tolerogenic and Immunogenic Dendritic Cell Maturation in Thymus and Periphery. Immunity (2016) 45:305–18. doi: 10.1016/j.jimmunol.2016.07.019
23. Vander Lugt B, Riddell J, Khan A, Hackney JA, Lesch J, Devoss J, et al. Transcriptional Determinants of Tolerogenic and Immunogenic States During Dendritic Cell Maturation. J Cell Biol (2017) 216:779–92. doi: 10.1083/jcb.201512012
24. Torres-Aguilar H, Aguilar-Ruiz SR, Gonzalez-Perez G, Munguia R, Bajana S, Bermejo-Jambrina M, et al. Global Quantification of Mammalian Gene Expression Control. Nature (2011) 473:337–42. doi: 10.1038/nature10098
25. Yuan S, Chen Y, Zhang M, Hu Z, Ruan Y, et al. Overexpression of miR-223 Promotes Tolerogenic Properties of Dendritic Cells Involved in Heart Transplantation Tolerance by Targeting Ikr1. Front Immunol (2021) 12:676337. doi: 10.3389/fimmu.2021.676337
26. Steimann RM, Nussenzweig MC. Avoiding Horror Autotoxicus: The Importance of Dendritic Cells in Peripheral T Cell Tolerance. Proc Natl Acad Sci U S A (2002) 99:351–8. doi: 10.1073/pnas.231606698
27. Clausen BE, Kel JM. Langerhans Cells: Critical Regulators of Skin Immunity? J Immunol Cell Biol (2010) 88:351–60. doi: 10.1089/jcb.2010.40
28. King JK, Phillips RL, Erickson AU, Kim JY, Halder RC, Lee DJ, et al. Langerhans Cells Maintain Local Tissue Tolerance in a Model of Systemic Autoimmune Disease. J Immunol (2015) 195:464–76. doi: 10.4049/jimmunol.1402735
29. Rissoan MC, Duhen T, Bridon JM, Bendriss-Vermare N, Peronne C, De Saint Vis B, et al. Subtractive Hybridization Reveals the Expression of Immunoglobulin-Like Transcript 7, Eph-B1, Granzyme B, and 3 Novel Transcripts in Human Plasmacytoid Dendritic Cells. Blood (2002) 106:3295–303. doi: 10.1182/blood-2002-02-0638
30. Salvi V, Verri C, Wavni A, Londera S, Carbone T, Facchetti F, et al. IL-21 May Promote Granzyme B-Dependent Plasmacytoid Dendritic Cell Functional Interaction in Cutaneous Lupus Erythematosus. J Invest Dermatol (2017) 137:1439–500. doi: 10.1016/j.jid.2017.03.016
31. Jahrsdorfer B, Vollmer A, Blackwell SE, Maier J, Sontheimer K, Beyer T, et al. Granzyme B Produced by Human Plasmacytoid Dendritic Cells Suppresses T-Cell Expansion. Blood (2010) 115:1156–65. doi: 10.1182/blood-2009-07-235382
32. Mossa A, Daoui A, Bounefy F, Aubergeon L, Saas P, Perruche S. Plasmacytoid Dendritic Cells Die by the CD8 T Cell-Dependent Perforin Pathway During Acute Nonviral Inflammation. J Immunol (2016) 197:1672–82. doi: 10.4049/jimmunol.1501875
33. Rissoan MC, Duhen T, Bridon JM, Bendriss-Vermare N. Cutaneous T Cell Lymphoma T-Cell Expansion. J Pathol (2003) 200:255–68. doi: 10.1016/j.path.1344
34. Vanbervliet B, Bendris-Vermare N, Massacrier C, Homey B, De Bouteiller O, Briere F, et al. The Inducible CXCR3 Ligands Control Plasmacytoid Dendritic Cell Responsiveness to the Constitutive Chemokine Stromal Cell-Derived Factor 1 (SDF-1)/Cxc12. J Exp Med (2003) 198:823–30. doi: 10.1084/jem.20024037
35. Banchereau J, Palucha AK. Dendritic Cells as Therapeutic Vaccines Against Cancer. Nat Rev Cancer (2005) 5:296–306. doi: 10.1038/nrc1592
36. Peguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J. Gangliosides From Human Melanoma Tumors Impair Dendritic Cell Differentiation From Monocytes and Induce Their Apoptosis. J Invest Dermatol (2009) 133:7488–94. doi: 10.4049/jid.2009-01233
37. Bennacrer K, Popa I, Chapman JA, Micald G, Peguet-Navarro J, Touraine JL, et al. Different Mechanisms are Involved in Apoptosis Induced by Melanoma Gangliosides on Human Monocyte-Derived Dendritic Cells. Glycobiology (2009) 19:576–82. doi: 10.1093/glycob/cwp015
38. Sombroek CC, Stamm AG, Masterson J, Lougheed SM, Schakel MJ, Meijer CJ, et al. Prostanoids Play a Major Role in the Primary Tumor-Induced Inhibition of Dendritic Cell Differentiation. J Immunol (2002) 168:4333–43. doi: 10.4049/jimmunol.168.9.433
39. Gottfried E, Kreutz M, Haffner S, Holler E, Iacobelli M, Andreesen R, et al. Differentiation of Human Tumour-Associated Dendritic Cells Into Endothelial-Like Cells: An Alternative Pathway of Tumour Angiogenesis. Scand J Immunol (2006) 68:329–35. doi: 10.1111/j.1365-8383.2007.01903.x
40. Jackson AM, Mulcahy LA, Zhu XW, O’donnell D, Patel PM. Tumour-Mediated Disruption of Dendritic Cell Function: Inhibiting the MEK1/2-
50. Enk AH, Jonuleit H, Saloga J, Knop J. Dendritic Cells as Mediators of Tolerance in Metastatic Melanoma. *Int J Cancer* (1997) 73:309–16. doi: 10.1002/(SICI)1097-0215(19971104)73:3<309::AID-IJC1>3.0.CO;2-3

51. Michea P, Noel F, Zakine E, Czerwinska U, Sirven P, Abozid O, et al. Adjustment of Dendritic Cells to the Breast-Cancer Microenvironment is Subset Specific. *Nat Immunol* (2018) 19:895–97. doi: 10.1038/s41591-018-0145-8

52. Di Blasio S, Van Wigcheren GF, Becker A, Van Duffelen A, Gorris M, et al. The Tumour Microenvironment Shapes Dendritic Cell Plasticity in a Human Organotypic Melanoma Culture. *Nat Commun* (2020) 11:2749. doi: 10.1038/s41467-020-16583-0

53. Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, et al. Activation and Antigen Expression. *J Exp Med* (2002) 196:541–9. doi: 10.1084/jem.20020732

54. Luo X, Zhou W, Zhang W, Li Z, Meng J, et al. Conversion of Human Dendritic Cells to Tumor-Induced Tolerance in Metastatic Melanoma. *Int J Cancer* (2015) 136:2224–35. doi: 10.1002/ijc.29169

55. Dunn GP, Koebel CM, Schreiber RD. Activation-Induced FOXP3 in Human T Effector Cells Does Not Suppress Proliferation or Cytokine Production. *Int Immunol* (2007) 19:1345–54. doi: 10.1093/intimm/dxm104

56. Santegoeds SJ, Dijkstra EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, et al. Monitoring Regulatory T Cells in Clinical Samples: Consensus on an Essential Marker Set and Gating Strategy for Regulatory T Cell Analysis by Flow Cytometry. *Cancer Immunol Immunother* (2015) 64:1271–86. doi: 10.1007/s00262-015-1729-x

57. Liu Z, Gerner MY, Van Panhuys N, Levine AG, Rudensky AY, Germain RN. Immune Homeostasis Enforced by Co-Localized Effector and Regulatory T Cells. *Nature* (2015) 528:225–30. doi: 10.1038/nature16169

58. Bolton HA, Zhu E, Terry AM, Guy TV, Koh WP, Tan ST, et al. Selective Treg Reconstitution During Lymphopenia Normalizes DC Cytostimulation and Prevents Granzyme-B-Host Disease. *J Clin Invest* (2015) 125:3627–41. doi: 10.1172/JCI76031

59. Predina J, Eruslanov E, Judy B, Kapoor V, Cheng GI, Wang LC, et al. Loss of Conventional Dendritic Cells Is Compatible With Various Autoimmune Diseases. *Immunity* (2015) 43:579–90. doi: 10.1016/j.immuni.2015.08.006

60. Krüger J, Ertl P, Belzer F, Schmidtmann I, Weck M, et al. Depletion of FoxP3+ Tregs Using the DEREG Mouse Model. *Methods Mol Biol* (Clifton N.J.) (2011) 707:157–72. doi: 10.1007/978-1-61737-979-6_10

61. Liu Z, Gerner MY, Van Panhuys N, Levine AG, Rudensky AY, Germain RN. DC in Tolerance and Immunity. *Front Immunol* | www.frontiersin.org June 2022 Volume 13 Article 929000

62. Koh W, Tan ST, Sim Y, Koh P, Tan SC, et al. T-Regulatory Cells Shift From a Protective Anti-Inflammatory to a Cancer-Promoting Proinflammatory Response Against Enteric Bacteria Helicobacter Hepaticus Induces Mammary Adenocarcinoma in Mice. *Cancer Res* (2008) 68:7399–400. doi: 10.1158/0008-5472.CAN-08-0578

63. Palczuk M, Blaut P, Schumacher TN, Wildenberg ME, Allison JP, et al. Synergism of Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade and Depletion of CD25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoimmune Cytotoxic T Lymphocyte Responses. *J Exp Med* (2001) 194:823–32. doi: 10.1084/jem.194.6.823

64. Krüger J, Ertl P, Belzer F, Schmidtmann I, Weck M, et al. Selective Treg Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination Against Established Melanoma. *Cancer Res* (2010) 70:7788–99. doi: 10.1158/0008-5472.CAN-10-1736

65. Rao VP, Pouthahidis T, Ge Z, Nambiar PR, Boussahmain C, Wang YY, et al. Innate Immune Inflammatory Response Against Enteric Bacteria Helicobacter Hepaticus Induces Mammary Adenocarcinoma in Mice. *Cancer Res* (2006) 66:7399–400. doi: 10.1158/0008-5472.CAN-06-0558

66. Gounaris E, Blatner NR, Dennis K, Magnusson F, Gurish MF, Strom TB, et al. Critical Function for Type I Interferons in Cancer Immunoediting. *Cancer Res* (2009) 69:5490–7. doi: 10.1158/0008-5472.CAN-09-0304

67. Koszulowska E, Chojnowska M, Czajkowska K, Cisowski J, et al. Lack of Conventional Dendritic Cells Is Compatible With Various Autoimmune Diseases. *Immunity* (2015) 43:579–90. doi: 10.1016/j.immuni.2015.08.006

68. Predina J, Eruslanov E, Judy B, Kapoor V, Cheng GI, Wang LC, et al. Changes in the Local Tumor Microenvironment in Recurrent Cancers may Explain the Failure of Vaccines After Surgery. *Proc Natl Acad Sci U S A* (2013) 110:5852–3. doi: 10.1073/pnas.1211850110

69. Li H, van der Leun AM, Yafe I, Lulbbing Y, Gelbard-Solodkin D, Van Akkooi ACJ, et al. Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment Within Human Melanoma. *Cell* (2019) 176:775–801.e718.
Scheib et al. DC in Tolerance and Immunity

102. Eriksson AU, Singh RR. Cutting Edge: Migration of Langerhans Dendritic Cells is Impaired in Autoimmune Dermatitis. J Immunol (2008) 181:7468–72. doi: 10.4049/jimmunol.181.11.7468

103. Sheng JP, Chen Q, Wu XT, Dong YW, Mayer J, Zhang JL, et al. Fate Mapping Analysis Reveals a Novel Murine Dermal Migratory Langerhans-Cell Population. Elife (2012) 1:e05541. doi: 10.7554/eLife.05541

104. Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of Psoriasis. Annu Rev Immunol (2014) 32:227–55. doi: 10.1146/annurev-immunol-032713-120225

105. Arakawa A, Siewert K, Stohr J, Besgen P, Kim SM, Ruhl G, et al. Melanocyte Antigen Triggers Autoimmunity in Human Psoriasis. J Exp Med (2015) 212:2203–12. doi: 10.1084/jem.20151093

106. Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, et al. The Antimicrobial Peptide LL37 Is a T-Cell Autoantigen in Psoriasis. Nat Commun (2015) 6:5621. doi: 10.1038/ncomms7595

107. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, et al. Psoriasis Is Characterized by Accumulation of Immunostimulatory and Th1/Th17 Cell-Polarizing Myeloid Dendritic Cells. J Invest Dermatol (2009) 129:79–88. doi: 10.1038/jid.2008.194

108. Flutter B, Nestle FO. TLRs to Cytokines: Mechanistic Insights From the Imiquimod Mouse Model of Psoriasis. Eur J Immunol (2013) 43:3138–46. doi: 10.1002/eji.201343801

109. Suarez-Farinas M, Arribet R, Jiang WW, Ortenzio FS, Sullivan T, Krueger JG. Suppression of Molecular Inflammatory Pathways by Toll-Like Receptor 7, 8, and 9 Antagonists in a Model of IL-23-Induced Skin Inflammation. Plos One (2013) 8(2):e86453. doi: 10.1371/journal.pone.0086453

110. Singh TP, Zhang HH, Borek I, Wolf P, Hedrick MN, Singh SP, et al. Monocyte-Derived Inflammatory Langerhans Cells and Dermal Dendritic Cells Mediate Psoriasis-Like Inflammation. Nat Commun (2016) 7:563–604. doi: 10.1038/ncomms13581

111. Alrashdan MS, Cirillo N, Mccullough M. Oral Lichen Planus: A Literature Review and Update. Arch Dermatol Res (2016) 308:539–51. doi: 10.1007/s00403-016-1667-2

112. Schmidt T, Soliman F, Pollmann R, Stein R, Schmidt A, Stulberg I, et al. (H1)/TH17 Cell Recognition of Desmoglein 3 and Bullous Pemphigoid Antigen 180 in Patients With Lichen Planus. J Allergy Clin Immunol (2018) 142:669–72. doi: 10.1016/j.jaci.2018.02.044

113. Santoro A, Majorana A, Roversi L, Gentili F, Marrelli F, Vermi W, et al. Recruitment of Dendritic Cells in Oral Lichen Planus. J Pathol (2005) 205:426–34. doi: 10.1002/path.1699

114. Posnett DN. Herpesviruses and Autoimmunity. Curr Opin Investigational Drugs (2008) 9:505–14.

115. Farias MA, Duarte LF, Tognarelli EL, Gonzalez PA. Herpes Simplex Virus Infection With Immunity: Focus on Dendritic Cells. Virulence (2012) 12:2583–607. doi: 10.1080/21505594.2012.1980990

116. De Vries HJC, Teunissen MMB, Zorgdrager F, Picavet D, Cornelissen M. Lichen Planus Remission is Associated With a Decrease of Human Herpes Virus Type 7 Protein Expression in Plasmacytoid Dendritic Cells. Arch Dermatol Res (2007) 299:213–9. doi: 10.1007/s00403-007-0750-0

117. Hasegawa H, Matsumoto T. Mechanisms of Tolerance Induction by Dendritic Cells In Vivo. Front Immunol (2018) 9:350. doi: 10.3389/fimmu.2018.00350

118. Castenmiller C, Kumatio-Doungtso BC, Van Ree R, De Jong EC, Van Kooyk Y. Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance. Front Immunol (2021) 12:645240. doi: 10.3389/fimmu.2021.645240

119. Passeri L, Marta F, Bassi V, Gregorio S. Tolerogenic Dendritic Cell-Based Approaches in Autoimmunity. Int J Mol Sci (2021) 22(16):8415. doi: 10.3390/ijms22168415

120. Iberg CA, Hawiger D. Natural and Induced Tolerogenic Dendritic Cells. J Immunol (2020) 204:733–44. doi: 10.4049/jimmunol.1901121

121. Stern JNH, Kesklin DB, Kato Z, Waldner H, Schallenberg S, Anderson A, et al. Promoting Tolerance to Proteolipid-Protein-Induced Experimental Autoimmune Encephalomyelitis Through Targeting Dendritic Cells. Proc Natl Acad Sci U S A (2010) 107:17280–5. doi: 10.1073/pnas.100263107

122. Ettinger M, Gratz IK, Gruber C, Hauser-Kronberger C, Johnson TS, Mahnke K, et al. Targeting of the Hn16a Collagen Domain to Dendritic Cells Induces Tolerance to Human Type XVII Collagen. Exp Dermatol (2012) 21:395–8. doi: 10.1111/j.1600-0625.2012.03474.x

123. Mukherjee G, Geliebter A, Babad I, Santamaria P, Serreze DV, Freeman GI, et al. DEC-205-Mediated Antigen Targeting to Steady-State Dendritic Cells
Induces Deletion of Diabetic CD8 T Cells Independently of PD-1 and PD-L1. *Int Immunol* (2013) 25:651–60. doi: 10.1038/imi.2013.10.

Squier R, Margry B, Keijzer C, Petzold C, Hoek A, Wagnera-Hilbers J, et al. DC205+ Dendritic Cell-Targeted Tollericin Vaccination Promotes Immune Tolerance in Experimental Autoimmune Arthritis. *J Immunol* (2015) 194:4804–13. doi: 10.4049/jimmunol.1400986.

Iberg CA, Hawiger D. Targeting Dendritic Cells With Antigen-Delivering Antibodies for Amelioration of Autoimmunity in Animal Models of Multiple Sclerosis and Other Autoimmune Diseases. *Antibodies (Basel)* (2020) 9 (2):23. doi: 10.3390/ab9020023.

Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, et al. Induction of Antigen-Specific Immunity With a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205. *Sci Transl Med* (2014) 6:232ra251. doi: 10.1126/scitranslmed.3008068.

Joffre OP, Sancho D, Zelenay S, Keller AM, Reis E Sousa C. Effect of MRP8/14, TLR4-, and TLR9-Mediated Immune Processes. *Allergen-Specific Nanoparticle Delivery of Donor Antigens for Transplant Tolerance in Autoimmune Disorders*. *Front Immunol* (2012) 3:135. doi: 10.3389/fimmu.2012.00135.

Clemente-Casares X, Blanco J, Ambalavanan P, Yamanouchi J, Singha S, Domogalla MP, Rostan PV, Raker VK, Steinbrink K. Tolerance Through TLR7-, and TLR9-Mediated Immune Processes. *Nat Immunol* (2015) 16:247–9. doi: 10.1038/ni.3467.

Kostner L, Anzengruber F, Guillod C, Recher M, Schmid-Grendelmeier P, Morante-Palacios O, Fondelli F, Ballestar E, Martinez-Caceres EM. Anergy in CD8(+) T Cells Induced by IL-10-Dependent ILT4/HLA-G Pathway. *J Invest Dermatol* (2003) 116:1634–22. doi: 10.1046/j.1523-1747.2003.1161634.x.

Kostner L, Anzengruber F, Guibaud C, Recher M, Schmid-Grendelmeier P, Navarini AA. Allergic Contact Dermatitis. *Immunol Allergy Clin North Am* (2017) 37:141–52. doi: 10.1016/j.iac.2016.08.014.

Azeem M, Kader H, Kerstan A, Hetta HF, Serfling E, Goebeler M, et al. Intricate Relationship Between Adaptive and Innate Immune System in Allergic Contact Dermatitis. *Yale J Biol Med* (2020) 93:699–709.

Lucky U, Maurer M, Schmidt T, Lorenz N, Seebach B, Metz M, et al. T Cell Blocking by Tolerogenic Dendritic Cells: Protection from Allergy. *J Clin Invest* (2011) 121:3860–71. doi: 10.1172/JCI45963.

Lucky U, Schmidt T, Pfender N, Romer M, Lorenz N, Martin SF, et al. Crossstalk of Regulatory T Cells and Tolerogenic Dendritic Cells Prevents Contact Allergy in Subjects With Low Zone Tolerance. *J Allergy Clin Immunol* (2012) 129:781. doi: 10.1067/jaci.2012.06.022.

Schmidt T, Lorenz N, Raker VK, Schmidgen MI, Mahnke K, Enk A, et al. Allergen-Specific Low Zone Tolerance Is Independent of MRPs/TLR-4, TLR-7, and TLR-9-Mediated Immune Processes. *J Invest Dermatol* (2018) 138:452–5. doi: 10.1093/jid/sjy277.

Wang J, Sampson HA. Safety and Efficacy of Epicutaneous Immunotherapy for Food Allergy. *Pediatr Allergy Immunol* (2018) 29:341–9. doi: 10.1111/pai.12869.

Dioszeghy V, Mondoulet L, Aouabi L, Dhelft V, Plaquet C, Boureaua A, et al. Antigen Uptake by Langerhans Cells Is Required for the Induction of Regulatory T Cells and the Acquisition of Tolerance During Epicutaneous Immunotherapy in OVA-Sensitized Mice. *Front Immunol* (2018) 9. doi: 10.3389/fimmu.2018.01951.

Domogalla MP, Rostan PV, Raker VK, Steinbrink K. Tolerance Through Education: How Tolerogenic Dendritic Cells Shape Immunity. *Front Immunol* (2017) 8. doi: 10.3389/fimmu.2017.01764.

Morante-Palacios O, Fendell F, Ballestar E, Martínez-Caceres EM. Tolerogenic Dendritic Cells in Autoimmunity and Inflammatory Diseases. *Front Immunol* (2021) 42:59–75. doi: 10.3389/fimmu.2020.01100.
160. Willekens B, Presas-Rodriguez S, Mansilla MJ, Derdelinckx J, Lee WP, Nijs G, et al. Tolerogenic Dendritic Cell-Based Treatment for Multiple Sclerosis (MS): A Harmonised Study Protocol for Two Phase I Clinical Trials Comparing Intradermal and Intranodal Cell Administration. BMJ Open (2019) 9:e030309. doi: 10.1136/bmjopen-2019-030309

161. Zubizarreta I, Florez-Grau G, Vila G, Cabezon R, Espana C, Andorra M, et al. Immune Tolerance in Multiple Sclerosis and Neuromyelitis Optica With Peptide-Loaded Tolerogenic Dendritic Cells in a Phase 1b Trial. Proc Natl Acad Sci U S A (2019) 116:8463–70. doi: 10.1073/pnas.1820039116

162. Jauregui-Amezaga A, Cabezon R, Ramirez-Morros A, Espana C, Rimola J, Bru C, et al. Intraperitoneal Administration of Autologous Tolerogenic Dendritic Cells for Refractory Crohn’s Disease: A Phase I Study. J Crohns Colitis (2015) 9:1071–8. doi: 10.1093/ecco-jcc/jv514

163. Sawitzki B, Harden PN, Reineke P, Moreau A, Hutchinson JA, Game DS, et al. Regulatory Cell Therapy in Kidney Transplantation (The ONE Study): A Harmonised Design and Analysis of Seven non-Randomised, Single-Arm, Phase 1/2A Trials. Lancet (2020) 395:1627–39. doi: 10.1016/S0140-6736(20)30167-7

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.